1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Communication Needed To Avoid Biosimilar ‘Nocebo’ Effect

Enhanced Communication Strategies Show Improvement In Patient Experience

 
• By Dave Wallace

Effective communication between doctors and patients when switching from a branded biologic to a biosimilar is needed to overcome the potential ‘nocebo’ effect, insisted Professor Fabrizio Benedetti at a EULAR symposium.

Doctor - patient
Effective communication with patients is needed to overcome the ‘nocebo’ effect for biosimilars • Source: Shutterstock

Effective communication between doctors and patients when switching from a branded biologic to a biosimilar is needed to overcome the potential adverse consequences of the ‘nocebo’ effect, according to Professor Fabrizio Benedetti of the department of neuroscience within Italy’s University of Turin.

Speaking at a European League Against Rheumatism (EULAR) virtual symposium on real-world evidence on the subject of “effective communication in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Polpharma Biologics And Fresenius Kabi Team Up On Entyvio Biosimilar

 
• By Urtė Fultinavičiūtė

Fresenius Kabi has picked up commercialization rights to Polpharma Biologics’ vedolizumab biosimilars in almost all markets. Still, the originator Takeda stands solid with no competition expected until at least 2032.

Celltrion And Arrotex Tie Up For A Pair Of First PBS-Listed Australian Biosimilars

 
• By Dean Rudge

Arrotex has entered into a strategic partnership with Celltrion Healthcare Australia to launch two first-to-market biosimilar medicines in Australia. These biosimilars, which treat chronic inflammatory conditions, are now listed on the PBS and available through pharmacies.

Cipla Revs Up Biosimilars Engine Amid Winds Of Regulatory Change

 
• By Anju Ghangurde

Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.

Samsung Bioepis’ Second Quarter Comes Down From Milestone-Boosted Q2 2024

 
• By Urtė Fultinavičiūtė

With the looming spin-off on the horizon, Samsung Bioepis looks at planned product launches and geographic expansion to maintain its annual revenue growth.

More from Products

Sandoz Rushes To Fill Gap After German Court Revokes Xarelto Patent

 
• By Dean Rudge

Germany’s Federal Patent Court has invalidated Bayer’s key patent covering once-daily use of Xarelto (rivaroxaban), paving the way for Sandoz to launch a generic version. Bayer is considering an appeal.

Samsung Bioepis’ Second Quarter Comes Down From Milestone-Boosted Q2 2024

 
• By Urtė Fultinavičiūtė

With the looming spin-off on the horizon, Samsung Bioepis looks at planned product launches and geographic expansion to maintain its annual revenue growth.

Medicines UK’s Samuels: Off-Patent Drugs Are Finally Gov’s Priority But The Picture Still ‘Nuanced’

 
• By Urtė Fultinavičiūtė

The importance of generic and biosimilar medicines is being recognized by the UK government for the first time. But, as Medicines UK’s CEO Mark Samuels tells Generics Bulletin, companies are still facing multiple hurdles in the market.